Toll-Like Receptor 4 Expression and Cytokine Responses in the Human Urinary Tract Mucosa

Patrik Samuelsson,1 Long Hang,1 Björn Wullt,1,2 Heikki Irjala,1,3 and Catharina Svanborg1

Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology,1 and Department of Urology,2 Lund University, Lund, Sweden, and Department of Otorhinolaryngology and Head and Neck Surgery, University of Turku, Turku, Finland3

Received 26 November 2003/Returned for modification 2 February 2004/Accepted 13 February 2004

Mucosal pathogens trigger a local innate host response by activating epithelial cells. Bacterial adherence and Toll-like receptor 4 (TLR4) signaling have been implicated as key events in this process. This study addressed the molecular basis of the epithelial response to gram-negative infection in the human urinary tract. Mucosal biopsies were obtained from kidneys, ureters, and bladders of patients undergoing urinary tract surgery, and epithelial TLR4 and CD14 expression was examined by immunohistochemistry. TLR4 was detected in epithelial cells lining the entire urinary tract and in the renal tubular epithelium. CD14, in contrast, was completely absent from the epithelial tissue. The response of the epithelial cells to infection was studied by in vitro challenge of the biopsies with uropathogenic Escherichia coli bacteria. A rapid cytokine response was observed, with production of interleukin-1β (IL-1β), IL-6, and IL-8 but not of IL-4 or gamma interferon. Adhering, P- or type 1-fimbriated E. coli activated IL-6 and IL-8 production more efficiently than the nonfimbriated control, as shown by cellular staining and analysis of secreted cytokines. The results demonstrate that human uroepithelial cells possess the molecular machinery needed to respond to uropathogenic E. coli. This includes recognition receptors for fimbriae and TLR4 for transmembrane signaling. We speculate that the lack of membrane-bound CD14 allows the epithelium to regulate its sensitivity to lipopolysaccharide and to discriminate between more-virulent and less-virulent strains.

Mucosal pathogens use diverse and highly sophisticated mechanisms to gain access to the tissues at their preferred site of infection (6, 8, 11, 35). Adherence is a crucial first step to establish tissue contact and to break the inertia of the mucosal barrier, but in addition, the molecular interactions between bacteria and host alert the host to the danger, and a host response is activated (1, 14). In urinary tract cell lines, epithelial cell activation by fimbriated Escherichia coli requires primary recognition receptors for fimbrial adhesins and Toll-like receptor 4 (TLR4) for transmembrane signaling (12). Human urinary tract epithelial cells express both glycosphingolipid and mannosylated surface glycoprotein receptors, which recognize the P fimbrial adhesins (29) and the type1 fimbriae, respectively (30). TLR4 is also expressed in murine urinary tract epithelium, and the trl4 genotype was found to regulate the in vivo response to experimental urinary tract infection (UTI) caused by P- or type 1-fimbriated E. coli (12, 17, 36, 38).

The extent to which TLR4 is expressed by the human urinary tract epithelium remains controversial, however. In addition, there are contradictory reports concerning the lipopolysaccharide (LPS) responsiveness of uroepithelial cells and their expression of CD14. It is well established that cells of myeloid origin express CD14 and MD2 and recruit TLR4 for transmembrane signaling when exposed to LPS (5), but uroepithelial cell lines respond poorly to soluble LPS even though they express TLR4 (23). This has been attributed to the lack of CD14 expression by those cells (2, 26). More recent studies of TLR4 and CD14 expression in urinary epithelial cell lines either have failed to demonstrate TLR4 or CD14 on the epithelium (3, 7) or have detected CD14 and proposed that LPS responsiveness is important in the urinary bladder (37). There are reports that urine contains soluble CD14 (sCD14) (7), but whether the concentration in uninfected urine is high enough to support CD14-mediated recognition of LPS needs further study.

Cytokines are early markers of the epithelial response to infection and play a key role in the innate defense (39). Interleukin-6 (IL-6) may cause fever and trigger the acute-phase response, while chemokines such as CXCL8 (IL-8) recruit inflammatory cells to the site of infection. The urine cytokine levels are elevated in patients with UTI (22, 31–33), and epithelial cells have been identified as early producers of cytokines in the murine UTI model (9, 20, 36), but the epithelial cytokine response of the human mucosa in situ has not been investigated.

This study used human urinary tract biopsies to characterize TLR4 and CD14 expression in the intact human urinary tract epithelium and to study the epithelial cytokine response to infection.

MATERIALS AND METHODS

Reagents. Monoclonal mouse anti-human IL-1β was from Genzyme, Cambridge, Mass.; anti-IL-4 and anti-gamma interferon (anti-IFN-γ) were from Mabtech AB, Stockholm, Sweden; anti-IL-6 (M16) was from Central Laboratory of The Netherlands’ Red Cross Blood Transfusion Service, Amsterdam, The Netherlands; and anti-IL-8 (NAP-1) was from Sandoz, Vienna, Austria. Mouse...
immunoglobulin G1 (IgG1) normal rabbit immunoglobulin, rabbit anti-mouse immunoglobulins, mouse alkaline phosphatase-anti-alkaline phosphatase complexes, and alkaline phosphatase-conjugated goat anti-rabbit antibody were from Dakopatts AB, Alvoj, Sweden. Fast-Red substrate was from Dako Corporation, Carpinteria, Calif. Dye compound was from Flow, Göteborg, Sweden; monoclonal mouse anti-human TLR4 (IMG-320) was from Imgenex, San Diego, Calif.; monoclonal mouse anti-human CD14 clone (TUK4), monoclonal mouse anti-human cytokeratin, monoclonal mouse IgG1 control, monoclonal mouse IgG2a control, swine anti-rabbit–fluorescein isothiocyanate (FITC), and rabbit anti-mouse–FITC were from Dako. Monoclonal mouse anti-human CD14 (clone MY4) was from Beckman Coulter, Miami, Fl. Lymphopherpep was from Axis-shield PoC AS, Oslo, Norway.

Patients. Biopsy specimens were obtained from 28 patients undergoing urinary tract surgery for a variety of diseases. The patients were divided into two groups, one with sterile urine at the time when the biopsy was obtained and one with asymptomatic bacteriuria (ABU). In the sterile urine group, nine patients underwent transurethral resection of the prostate due to benign prostate hyperplasia. Only bladder specimens were obtained from this group. Seven patients underwent nephroureterectomy, nephrectomy, or cystectomy due to cancer of the kidney, renal pelvis, or bladder. Bladder biopsies were obtained from two patients, renal pelvis biopsies were obtained from five patients, renal cortex biopsies were obtained from two patients, and urethral biopsies were obtained from two patients. Renal pelvis biopsies were also obtained from two patients undergoing pyeloplasty due to hydronephrosis and heminephrectomy due to a duplication of the renal pelvis.

In the bacteriuria group, all patients were asymptomatic, and only one had received antibiotic treatment during the last 30 days. Bladder biopsies were obtained from four patients undergoing transurethral resection due to benign prostate hyperplasia. These patients had indwelling catheters. One bladder biopsy was obtained from a patient undergoing cystectomy due to bladder cancer. One bladder biopsy was obtained from a patient with a neurogenic bladder disorder. Renal pelvis biopsies were obtained from three patients undergoing nephrectomy due to chronic pyelonephritis and from one patient undergoing nephrectomy due to renal cancer.

All biopsies from cancer patients were obtained from areas well outside tumor growth and were confirmed as tumor free by the pathologist. This study was approved by the Ethics Committee of the Medical Faculty at Lund University.

Urine samples. Morning urine was collected prior to surgery and before antibiotic treatment was given. Samples were kept at 4°C until freshly quantitated. The urine isolates were examined by Gram staining and were further identified by standard laboratory techniques.

Collection of biopsies. The biopsies were obtained 10 to 30 min after cutting off the blood supply and were cut to pieces of 5 by 5 by 5 mm. The pieces were embedded in OCT compound, rapidly frozen in liquid nitrogen, and kept at −80°C or were stimulated with bacteria in vitro prior to freezing (see below).

Bacteria. Uropathogenic E. coli isolates or recombinant strains differing in fimbrial expression were used for in vitro infection of the biopsies. E. coli HU734 is a lac mutant of the wild-type pyelonephritis strain GR12 (serotype O75/K5: HO: lly ColV “pap + fim +”) (16). E. coli HB101 (pap) is a K-12 derivative lacking most virulence genes. The strain was used as a host for the recombinant plasmid pPH110-35 encoding P fimbriae (pap +). The plasmid carried a 16-kb EcoRI fragment from the AD110 pap gene cluster inserted in the EcoRI site of pA-CYC184 (41). The K-12 derivative E. coli AACEC 191A (fim) was used as a recipient for the recombinant plasmid pPKL4, encoding type 1 fimbriae. E. coli PKL4 (fim +) carried the entire fim gene cluster from E. coli PC31 isolated into the tetracycline site of pH322 (27).

The strain was maintained on tryptic soy agar and subcultured overnight in Luria broth with appropriate selection at 37°C for in vitro infection. After centrifugation, the bacterial pellet was washed three times by repeated cycles of centrifugation at 2,800 × g for 10 min and resuspension in phosphate-buffered saline (PBS). The bacteria were finally diluted in RPMI to about 10⁶ CFU per ml. Type 1 and P fimbrial expression was tested by receptor-specific hemagglutination tests (29).

Infection of biopsies. All of the biopsies from bladder and pelvis that were large enough to be divided were included in the in vitro infection study. Fresh biopsy pieces were washed once in RPMI and transferred to 24-well plates in triplicate. Tissue culture medium or medium containing E coli bacteria (10⁸ CFU/ml) was added, and the plates were incubated at 37°C in a 5% CO₂ atmosphere with shaking. Tissue supernatants were harvested after 0, 2, and 6 h and centrifuged at 2,800 × g for 10 min, and supernatants were stored at −80°C for cytokine analysis. One piece each was collected at 0, 2, and 6 h and frozen as described above. For IL-8, additional biopsies were harvested after 30 min.

Cytokine analysis by immunohistochemistry. The embedded tissues were sectioned in a cryostat (Carl Zeiss AB, Stockholm, Sweden) into 6-μm sections and mounted on poly-L-lysine-coated glass slides. For staining of intracellular cytokines, sections were fixed in freshly prepared 4% paraformaldehyde (34) for 15 min, rinsed in PBS (0.06 M, pH 7.2), air dried, and kept at −20°C until used. The sections were permeated with 0.1% saponin (34) in PBS containing 5% heat-inactivated normal human AB serum for 60 min at room temperature to reduce nonspecific binding. After being washed in PBS–0.1% saponin three times, the sections were incubated overnight at 4°C with a panel of cytokine-specific monoclonal antibodies at a concentration of 5 to 10 μg/ml. After being washed with 0.1% saponin in Tris-buffered saline (TBS-Sap), the sections were incubated with rabbit anti-mouse immunoglobulins for 60 min at room temperature in a moist chamber. The sections were washed again in TBS-Sap and incubated with mouse alkaline phosphatase–anti-alkaline phosphatase complexes in TBS-Sap for 60 min as described above. After three washes in TBS-Sap, the Fast-Red substrate with Fast-Red chromogen was added (according to the manufacturer’s instructions) and left to incubate for 20 min. The sections were thereafter washed in TBS (pH 7.6), counterstained with hematoxylin for 5 to 10 s, and mounted with Mount-Quick “AQUEOUS.” Mouse IgG1 at a final concentration of 5 to 10 μg/ml and a normal rabbit immunoglobulin fraction were used as negative controls.

Three to five sections from each biopsy were inspected single blind by light microscopy. The intensity of cytokine staining was given as the number of positive epithelial cells after scoring of at least 200 cells per section.

TLR4 and CD14 analysis by immunohistochemistry. Sections were fixed on polylysine-coated slides in acetone for 3 min, air dried, and kept at −80°C until used. Sections were incubated with primary antibody (diluted in PBS) for 60 min at room temperature. After incubation, they were washed twice in PBS. The sections were incubated with the secondary antibody (alkaline phosphatase-conjugated rabbit anti-mouse antibody diluted in 5% AB serum) for 60 min and washed twice in PBS. The sections were then incubated with Fast-Red substrate for 20 min and were further treated as were the cytokine stainings described above.

Analysis of TLR4 and CD14 on excreted urinary cells by flow cytometry. Urine samples were received from four healthy females. The urine was centrifuged at 260 × g for 30 min to pellet the shed epithelial cells. The cells were washed in PBS–0.1% bovine serum albumin (BSA), and 2 × 10⁵ cells were incubated with the primary antibody (rabbit anti-human TLR4, mouse anti-human CD14, or control antibody) diluted in 100 μl of PBS–0.1% BSA for 1 h at 4°C. The cells were washed twice in PBS–0.1% BSA and incubated with the secondary antibody (swine anti-rabbit–FITC or rabbit anti-mouse–FITC). The cells were washed twice and analyzed in a flow cytometer (FACScalibur; Becton Dickinson).

Antibody specificity. The specificity of the anti-TLR4 monoclonal antibody was confirmed by using native HEK-293 cells lacking tlr4 (CRL-1573; American Type Culture Collection, Manassas, Va.) and the tlr4-transfected HEK-293 cell line (43). The specificity of the anti-CD14 antibodies was confirmed by using human peripheral blood monocytes. The mononuclear cells were isolated with Lymphoprep according to the manufacturer’s instruction. Adherent cells were enriched by adsorption to a plastic slide, followed by washing three times to remove nonadherent cells. The monocytes were detached with PBS-EDTA and stained with anti-CD14 antibodies or an isotype-matched negative control antibody.

Quantitation of IL-6 and IL-8. Secreted IL-8 was quantified by enzyme-linked immunosorbent assay with monoclonal mouse anti-human IL-8 IgG (1 to 5 μg/ml) as the primary antibody and polyclonal goat anti-mouse IgG conjugated to alkaline phosphatase as the secondary antibody. The lower detection limit of the assay was 7.5 pg/ml. IL-6 was quantified by enzyme-linked immunosorbent assay with monoclonal mouse anti-human IL-6 IgG (2 mg/ml) as the primary antibody and polyclonal goat anti-mouse IgG conjugated to biotin as the secondary antibody. The lower detection limit of this assay was 7.5 pg/ml.

Statistical analysis. Fisher’s exact test, the Spearman rank correlation test, and the unpaired t test were used. Differences were considered significant for P values of <0.05.
RESULTS

**TLR4 expression in the human urinary tract mucosa.** TLR4 expression in biopsies from five patients with sterile urine was examined. Sections were stained with a monoclonal anti-human TLR4 antibody (IMG-320) and visualized with Fast-Red substrate. TLR4 (red) was detected in the epithelium (asterisks) lining the bladder, ureter, pelvis, and cortex. (Right panels) The isotype control antibody did not stain the sections. Magnification, ×200.

**CD14 is not expressed in the urinary tract epithelium.** The tissue sections were subsequently stained for CD14, using two different monoclonal antibodies (clones TÜK4 [Fig. 3] and MY4 [data not shown]). CD14 was not detected in epithelial cells from any part of the urinary tract, but occasional cells in the subepithelial compartment were CD14 positive. The specificity of the anti-CD14 antibodies was confirmed by staining of peripheral blood monocytes (Fig. 2E).

**Mucosal cytokine profile in native biopsies.** Epithelial cytokine expression in the urinary bladder and renal pelvis was examined in serial sections of biopsies from patients with sterile urine or bacteriuria. The epithelial cytokine content was characterized by immunohistochemistry and quantified by counting of 200 epithelial cells in each sample (Table 1). Examples of epithelial staining are given in Fig. 4A to C. Preformed IL-8 was detected in the epithelial cells of all of the sterile biopsies, with a cellular frequency ranging from about 50 to 100%. Some individuals showed IL-1β staining, and one showed IL-6 staining in the renal pelvis, but there was no expression of IL-4 or IFN-γ.

Biopsies were also collected from 10 patients who had sig-
significant bacteriuria at the time of surgery but no symptoms of infection. Five patients carried *E. coli*, and five carried gram-positive bacteria. The epithelial cytokine content of their biopsies is summarized in Table 1. All but one of the bacteriuric patients showed epithelial IL-8 staining, with a frequency of positive cells ranging from 40 to 100%. IL-6 was detected in only two biopsies, which also contained some inflammatory cells. IL-1β staining was detected in all but one of the biopsies from the bacteriuric patients (9 of 10, compared to 5 of 13 biopsies from patients with sterile urine [P < 0.05]). IFN-γ was detected in one infected patient, but these cells did not show epithelial morphology. IL-4 was not detected at all. Thus, except for IL-1β, there was no significant difference in epithelial cytokine content between biopsies from patients with sterile urine and those from patients with ABU.

**Infection stimulates epithelial cytokine production.** The mucosal cytokine response to infection was examined by bacterial challenge of individual biopsies from the urinary bladder and

![CD14 and Cytokeratin](image)

**Fig. 3.** CD14 is not expressed by the human urinary tract epithelium. (Left panels) Biopsies were stained with the anti-CD14 antibody TUK4 (epithelium is marked by asterisks). CD14 was not detected in the epithelium of the bladder, ureter, renal pelvis, or cortex. Weak CD14 staining was observed between the tubuli (G), probably reflecting the presence of serum. Occasional CD14-positive myeloid cells were detected under the epithelium. Similar results were obtained by staining with the CD14-specific antibody MY4 (not shown). (Right panels) Control sections were stained with the epithelial cell cytokeratin antibody MNF116. Magnification, ×200.

![Before and After infection](image)

**Fig. 4.** Epithelial cytokine response to bacterial challenge. Human biopsies were challenged with a uropathogenic *E. coli* strain. Sections were stained with monoclonal anti-IL-8 (A, D, and E), IL-6 (B and F), and IL-1β (C and G) antibodies. Tissue sections are shown before (left panels) or after (right panels) infection with *E. coli* Ha734. Magnification, ×200.

### Table 1. Epithelial cytokine expression in urinary tract biopsies

<table>
<thead>
<tr>
<th>Urine</th>
<th>Biopsy location (n)</th>
<th>IL-1β</th>
<th>IL-6</th>
<th>IL-8</th>
<th>IL-4</th>
<th>IFN-γ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterile Bladder (8)</td>
<td>2/8 (15–17.5)</td>
<td>0/8</td>
<td>8/8 (49–100)</td>
<td>0/8</td>
<td>0/8</td>
<td></td>
</tr>
<tr>
<td>Pelvis (5)</td>
<td>3/5 (15–100)</td>
<td>1/5 (9)</td>
<td>5/5 (44–100)</td>
<td>0/5</td>
<td>0/5</td>
<td></td>
</tr>
<tr>
<td>ABU Bladder (6)</td>
<td>6/6 (23.5–73)</td>
<td>1/6 (17.5)</td>
<td>6/6 (40–100)</td>
<td>0/6</td>
<td>0/6</td>
<td></td>
</tr>
<tr>
<td>Pelvis (4)</td>
<td>3/4 (34–100)</td>
<td>1/4 (16)</td>
<td>3/4 (44–100)</td>
<td>0/4</td>
<td>0/4</td>
<td></td>
</tr>
</tbody>
</table>

* P value:
  - < 0.05: NS
  - NS: NS

* Two patients had gram-positive bacteriuria, and four had gram-negative bacteriuria.
* One patient had gram-positive bacteriuria, and three had gram-negative bacteriuria.
* One sample contained nonepithelial IFN-γ positive cells.
* Sterile urine versus ABU.
* NS, not significant.
renal pelvis, and the epithelial cytokine content was characterized by immunohistochemistry. The response to infection was defined as the change in epithelial cytokine content after bacterial challenge, by counting of 200 epithelial cells in each section (Fig. 4D to G and 5).

The biopsies were first exposed to the uropathogenic *E. coli* strain Hu734. Prior to infection, IL-8 was present in the epithelial lining in all of the biopsies, with the most intense staining in the apical compartment of the epithelial cells. Shortly after infection (30 min), there was a decrease in the epithelial IL-8 content, suggesting that infection triggers IL-8 secretion (see example in Fig. 4D). After 6 h, IL-8 had accumulated in the epithelium, indicating de novo synthesis. The release of IL-8 was confirmed by analysis of cytokines in tissue supernatants obtained before infection and at 2 and 6 h after infection (*P* < 0.001 compared to the uninfected controls) (Table 2).

The epithelial IL-6 response to in vitro infection with virulent *E. coli* is shown in Fig. 4F and 5. IL-6 was detected within 2 h, and after 6 h, the epithelial IL-6 content had increased further. There was no preformed IL-6, but secretion increased with time after *E. coli* infection (Table 2) (*P* < 0.001 compared to the uninfected controls). Low-level IL-1β expression was detected in uninfected epithelium, but after in vitro infection, a strong increase in epithelial IL-1β was observed (Fig. 4C and G and 5). Release of IL-1β was not measured, but other studies have shown that this cytokine is not secreted from epithelial cells of the urinary tract (13, 21, 28). IL-4 and IFN-γ were not detected in the epithelium after in vitro infection (not shown).

No significant differences in the cytokine response to in vitro challenge could be seen between biopsies from the urinary bladder and renal pelvis or between biopsies from patients with sterile urine and ABU.

**TABLE 2. Epithelial cytokine response to in vitro challenge with *E. coli***

<table>
<thead>
<tr>
<th>Strain</th>
<th>Cytokine</th>
<th>h</th>
<th>Cytokine secretion (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Challenge</td>
</tr>
<tr>
<td>Hu734</td>
<td>IL-6</td>
<td>0</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>612 ± 73</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>2,692 ± 395</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>0</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>934 ± 240</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>11,460 ± 1,238</td>
</tr>
<tr>
<td>pap</td>
<td>IL-6</td>
<td>0</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>1,060 ± 233</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>4,342 ± 152</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>0</td>
<td>119 ± 36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>433 ± 132</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>14,352 ± 647</td>
</tr>
<tr>
<td>fim</td>
<td>IL-6</td>
<td>0</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>1,451 ± 307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>4,284 ± 190</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>0</td>
<td>100 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>1,538 ± 967</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>16,896 ± 744</td>
</tr>
</tbody>
</table>

$^a$ Cytokines in supernatants obtained at various times after in vitro challenge of the biopsies were quantified. Values are means ± standard errors of the means.

$^b$ Control biopsies were incubated in RPMI. Controls for the *pap*+ and *fim*+ strains were *pap*- and *fim*-negative strains, respectively.

$^c$ NS, not significant.

**P and type 1 fimbriae amplify the mucosal cytokine response.** The biopsies were subjected to in vitro infection with recombinant *E. coli* strains differing in *P* or type 1 fimbrial expression. The fimbriated *pap*+ and *fim*+ strains caused strong and rapid IL-6 responses. Increases in epithelial staining were detected after 2 h, with further increases after 6 h. The nonfimbriated control strains caused a lower and delayed response.

The results were confirmed by analysis of cytokine secretion in the supernatants from the biopsies infected with fimbriated bacteria. The kinetics are shown in Table 2. After 6 h there was a significant difference in the concentrations of IL-6 and IL-8 compared to control strains.

**DISCUSSION**

The urinary tract is frequently challenged by invading microorganisms, but in most individuals, sterility is rapidly regained. An efficient mucosal sensing machinery identifies the pathogens and recruits the innate antimicrobial defense. The epithelial cells, which form the critical barrier to microbial attack, are the first source of defense molecules, and the molecular interactions that determine epithelial cell activation are fundamental to pathogenesis. In the murine model, *tlr4* has been shown to control epithelial responses to virulent *E. coli* bacteria (12, 17, 38). The present study examined the molecular basis for epithelial responses to infection in the urinary
tract epithelium. TLR4 expression was detected in epithelial cells along the entire human urinary tract, thus providing the basis for TLR4 to control the innate mucosal response to infection also in humans.

As most uropathogens are gram negative, LPS would be the expected ligand/agonist triggering TLR4 signaling. Paradoxically, uroepithelial cells respond poorly to LPS challenge in vitro (26). The present study demonstrated that CD14 is absent from the human urinary tract epithelium, thus providing an explanation for the poor response both to soluble LPS and to avirulent strains of E. coli. This poor response to avirulent strains has been documented in large clinical studies. Most patients with ABU carry between 10^5 and 10^8 CFU/ml of urine, and still there is no evidence of mucosal inflammation. Fewer than 20% of the ABU strains express P fimbriae, and they adhere poorly to uroepithelial cells despite possessing the genetic machinery required to express type 1 fimbriae (11, 18, 19). Virulent strains, on the other hand, were able to activate a primary kidney epithelial cell line, A498, and the cells were shown to respond poorly to soluble LPS (23, 26). More recently, CD14 was detected in bladder cell lines, and LPS was proposed to trigger the mucosal response to urinary tract infection via the CD14-dependent TLR4 pathway (37). The present study showed that CD14 is absent from the human urinary tract epithelium and that infection fails to trigger CD14 expression in those cells.

The lack of membrane-bound CD14 in the epithelium is consistent with the nonmyeloid origin of those cells. Furthermore, the epithelium was shown to respond to E. coli challenge also in the absence of CD14. These results do not exclude the involvement of CD14 in mucosal responses, however. The soluble form of CD14 has been shown to enhance epithelial LPS responses in vitro (2, 40). sCD14 may be secreted into the urine during infection and may enhance the continued response to infection (2, 7). Bussolati et al. (7) showed that urinary LPS-CD14 complexes from proteinuric patients could activate a primary kidney epithelial cell line, and LPS was shown to activate epithelial cell lines in vitro in the presence of both sCD14 and LBP. It remains to be studied whether the concentration of sCD14 and LPS-binding protein in the urine of uninfected patients is sufficient for an LPS-LBP-CD14-dependent signal to occur. As the concentration of sCD14 increases after infection, the CD14-dependent pathways may take over during later stages of infection.

P or type 1 fimbriae were shown to enhance the epithelial cytokine response of the human biopsies. This is consistent with in vitro studies in human cell lines and with results from the murine UTI model and confirms the effect of adherence on epithelial cell activation (12, 15, 23, 26). In contrast, the mucosa was quite inert to the nonfimbriated control strains. Two
mechanisms have been offered to explain how fimbia-mediated adherence can break mucosal inertia. One involves TLR4 activation through modification of the recognition receptor for the fimbiae (25). The second involves fimbiae as presenters of LPS, which compensate for the lack of membrane-bound CD14 by delivering LPS in the proximity of TLR4. This mechanism was previously examined by mutational detoxification of lipid A in P- or type 1-fimbriated E. coli strains (24, 26). msbB mutations did not reduce the response to P-fimbriated bacteria, suggesting that TLR4 activation is through a partly LPS-independent mechanism. By using the same experimental approach, type 1 fimbiae were shown to differ from P fimbiae in that they can constitute LPS delivery vehicles (24). These experiments illustrate the diversity of molecular cross talk between pathogens and epithelial cells.

The present study further emphasizes the difference in the handling of gram-negative bacteria between the mucosal and the systemic compartments. Macrophages and other TLR4/CD14-positive cells respond promptly to LPS (42) but are less able than the epithelial cells to discriminate between more or less pathogenic gram-negative bacteria. Such indiscriminate recognition may be desirable in the systemic compartment, where the main defense function is to maintain tissue sterility at any cost and where the presence of even the least virulent organism poses a potential threat. Epithelial cells, on the other hand, encounter a diverse gram-negative flora and need to separate LPS-bearing, nonpathogenic strains from the pathogens. The presence of TLR4 and the lack of membrane CD14 may explain why ABU strains often fail to trigger a mucosal response. We thank I. Lindley and M. Ceska (Sandoz, Vienna, Austria) for kindly supplying recombinant IL-8, and polyclonal rabbit anti-human IL-8 antibody and Christina Ehlels of human origin. Infect. Immun. 70:717–725.


ACKNOWLEDGMENTS

REFERENCES


